← All trials
NCT04921254
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Jun 30, 2022
- First posted
- Jun 10, 2021
- Last posted
- Jun 10, 2021
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biosergen ASLead sponsor
- Nucleus Network LtdCollaborator
- Greenlight ClinicalCollaborator
- Select Pharma Pty LtdCollaborator
- Nucleus Network LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.